BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Park S, Choi S, Cho YA, Sinn DH, Kim JM, Park CK, Ha SY. Evaluation of the American Joint Committee on Cancer (AJCC) 8th Edition Staging System for Hepatocellular Carcinoma in 1,008 Patients with Curative Resection. Cancer Res Treat 2020;52:1145-52. [PMID: 32599989 DOI: 10.4143/crt.2020.208] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Korean Liver Cancer Association (KLCA) and National Cancer Center (NCC) Korea. 2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma. Clin Mol Hepatol 2022;28:583-705. [PMID: 36263666 DOI: 10.3350/cmh.2022.0294] [Reference Citation Analysis]
2 Zhang W, Wan Y, Zhang Y, Liu Q, Zhu X. CSTF2 Acts as a Prognostic Marker Correlated with Immune Infiltration in Hepatocellular Carcinoma. Cancer Manag Res 2022;14:2691-709. [PMID: 36117731 DOI: 10.2147/CMAR.S359545] [Reference Citation Analysis]
3 Zheng Z, Guan R, Zou Y, Jian Z, Lin Y, Guo R, Jin H. Nomogram Based on Inflammatory Biomarkers to Predict the Recurrence of Hepatocellular Carcinoma-A Multicentre Experience. J Inflamm Res 2022;15:5089-102. [PMID: 36091335 DOI: 10.2147/JIR.S378099] [Reference Citation Analysis]
4 Qiu Y, Yang Y, Wang T, Shen S, Wang W. Efficacy of Postoperative Adjuvant Transcatheter Arterial Chemoembolization in Hepatocellular Carcinoma Patients With Microscopic Portal Vein Invasion. Front Oncol 2022;12:831614. [DOI: 10.3389/fonc.2022.831614] [Reference Citation Analysis]
5 Zhang Y, Cheng J, Zhong C, Xia Q, Li Y, Chen P, Fan X, Mao Q, Lin H, Hong D. ESR1 Regulates the Obesity- and Metabolism-Differential Gene MMAA to Inhibit the Occurrence and Development of Hepatocellular Carcinoma. Front Oncol 2022;12:899969. [DOI: 10.3389/fonc.2022.899969] [Reference Citation Analysis]
6 Nahm JH, Park YN. [Up-to-date Knowledge on the Pathological Diagnosis of Hepatocellular Carcinoma]. Korean J Gastroenterol 2021;78:268-83. [PMID: 34824185 DOI: 10.4166/kjg.2021.140] [Reference Citation Analysis]
7 Xu L, Jian X, Liu Z, Zhao J, Zhang S, Lin Y, Xie L. Construction and Validation of an Immune Cell Signature Score to Evaluate Prognosis and Therapeutic Efficacy in Hepatocellular Carcinoma. Front Genet 2021;12:741226. [PMID: 34646307 DOI: 10.3389/fgene.2021.741226] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Deng X, Cheng J, Zhan N, Chen J, Zhan Y, Ni Y, Liao C. MicroRNA-135a expression is upregulated in hepatocellular carcinoma and targets long non-coding RNA TONSL-AS1 to suppress cell proliferation. Oncol Lett 2021;22:808. [PMID: 34630715 DOI: 10.3892/ol.2021.13069] [Reference Citation Analysis]
9 Li X, Zhang X, Li Z, Xie C, Qin S, Yan M, Ke Q, Jin X, Lin T, Zhou M, Liang W, Qi Z, Geng Z, Quan X. Two-Trait Predictor of Venous Invasion on Contrast-Enhanced CT as a Preoperative Predictor of Outcomes for Early-Stage Hepatocellular Carcinoma After Hepatectomy. Front Oncol 2021;11:688087. [PMID: 34540664 DOI: 10.3389/fonc.2021.688087] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Zhang EL, Cheng Q, Huang ZY, Dong W. Revisiting Surgical Strategies for Hepatocellular Carcinoma With Microvascular Invasion. Front Oncol 2021;11:691354. [PMID: 34123861 DOI: 10.3389/fonc.2021.691354] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]